Evidence deep dives for Pulmonary Fibrosis
Pair mechanism-level evidence with practical protocol context before discussing next steps with your veterinarian.
A Progressive Disease That Steals Breath Slowly
Pulmonary fibrosis is a chronic, progressive lung disease in which normal lung tissue is gradually replaced by scar tissue (fibrosis). As the fibrosis advances, the lungs lose their elasticity and their ability to exchange oxygen and carbon dioxide efficiently. The result is a dog that slowly, inexorably runs out of air.
The disease is sometimes called idiopathic pulmonary fibrosis (IPF) when no underlying cause can be identified — which is the case in most dogs. It is also referred to as “Westie lung disease” because the West Highland White Terrier is by far the most commonly and most severely affected breed, though other terrier breeds and some non-terrier breeds can also develop it.
Pulmonary fibrosis is not curable. Unlike an infection that can be cleared or a tumor that can be removed, the scarring process cannot be reversed once established. Treatment focuses on slowing progression and maintaining quality of life for as long as possible.
How Lung Scarring Develops
In healthy lungs, oxygen crosses from the air spaces (alveoli) into the blood through an extremely thin membrane — the alveolar-capillary barrier. This membrane is measured in fractions of a micron. Even tiny increases in its thickness impair gas exchange significantly.
In pulmonary fibrosis, the pathological process begins in the interstitium — the supportive tissue framework between the alveoli. Abnormal fibroblast activation leads to excessive collagen deposition, thickening the interstitial tissue and stiffening the lung parenchyma. The alveolar walls become rigid and thickened. The alveoli themselves may collapse or become distorted.
The consequences compound over time:
- Impaired oxygen exchange: The thickened alveolar walls create a barrier to oxygen diffusion. Blood oxygen levels drop, initially only during exertion, then progressively at rest.
- Reduced lung compliance: The lungs become stiff, requiring more effort to expand. Breathing becomes visibly labored.
- Pulmonary hypertension: The fibrotic lung tissue compresses and obliterates small blood vessels, increasing resistance in the pulmonary circulation. The right side of the heart must work harder, eventually leading to right-sided heart failure (cor pulmonale).
- Exercise intolerance: The combination of poor oxygenation and increased breathing effort creates progressive exercise limitation.
The trigger for this fibrotic cascade is unknown in idiopathic cases. Potential contributing factors include chronic low-grade respiratory infections, environmental irritant exposure, gastroesophageal reflux with micro-aspiration, and genetic predisposition. In Westies, a strong hereditary component is suspected.
Clinical Signs
Pulmonary fibrosis develops gradually, and early signs are easily attributed to aging or being “out of shape.”
Early signs (often missed):
- Mild exercise intolerance: your dog tires faster than expected on walks, stops sooner than usual
- Slightly increased respiratory rate, particularly after mild exertion
- Occasional dry cough, non-productive
- Normal appetite and behavior otherwise
Progressive signs:
- Persistent exercise intolerance that limits normal daily activities
- Increased respiratory rate at rest (normal for a dog at rest is below 30 breaths per minute)
- Chronic, non-productive cough that may be triggered by excitement, exertion, or pulling on the leash
- Audible crackles (Velcro-like sounds) heard through a stethoscope on lung auscultation
- Cyanosis (blue-tinged gums and tongue) after exertion or in advanced cases even at rest
- Weight loss from the increased metabolic cost of breathing
Late-stage signs:
- Severe respiratory distress at rest
- Syncope (fainting) during exertion due to hypoxemia
- Abdominal distension (ascites from right-sided heart failure)
- Open-mouth breathing
- Reluctance to lie down (orthopnea — breathing is harder in recumbent positions)
The key clinical warning: any middle-aged to senior West Highland White Terrier with exercise intolerance and chronic cough should be evaluated for pulmonary fibrosis.
How Your Vet Will Identify This
Thoracic radiographs: The first-line imaging study. Classic findings include a diffuse bronchointerstitial to interstitial pattern, often described as a “ground glass” opacity or diffuse reticular pattern. Radiographic changes may be subtle early in the disease and dramatic in advanced cases.
High-resolution CT (HRCT): Provides far more detail than radiographs and can identify fibrotic changes earlier. Characteristic findings include ground-glass opacities, traction bronchiectasis (distorted airways pulled by surrounding fibrosis), and honeycombing in advanced cases. HRCT is the best non-invasive imaging modality for pulmonary fibrosis.
Arterial blood gas analysis or pulse oximetry: Documents hypoxemia (low blood oxygen). Pulse oximetry is easily performed and useful for monitoring disease progression. Oxygen saturation below 95% at rest or below 90% after a 6-minute walk is concerning.
Echocardiography: Assesses for pulmonary hypertension and right-sided heart changes. Elevated estimated pulmonary artery pressure or right ventricular enlargement indicates significant pulmonary vascular compromise.
Bronchoalveolar lavage (BAL): Can help rule out infectious or inflammatory causes of lung disease but does not definitively confirm fibrosis.
Lung biopsy: Provides the definitive diagnosis but is rarely performed in clinical practice due to the risks of general anesthesia and thoracotomy in a dog with already compromised lung function.
Treatment: Managing What Cannot Be Cured
There is no treatment that reverses established pulmonary fibrosis in dogs. Management focuses on three goals: slowing progression, treating complications, and maintaining quality of life.
Anti-fibrotic therapy:
- There are no FDA-approved anti-fibrotic drugs for dogs. In human medicine, pirfenidone and nintedanib have shown modest benefit in slowing IPF progression, and some veterinary specialists are beginning to use these drugs off-label in dogs, though evidence for canine efficacy is limited and cost is substantial.
Symptomatic treatment:
- Bronchodilators (theophylline, terbutaline): May improve airflow and reduce cough, though response is variable. Not all dogs benefit.
- Low-dose corticosteroids: Prednisolone at anti-inflammatory doses (0.5-1 mg/kg/day) may reduce the inflammatory component of the disease in some dogs. Response is inconsistent, and long-term steroid use carries its own risks.
- Cough suppressants (hydrocodone, butorphanol): Used when coughing significantly impairs quality of life. Cough suppression does not address the underlying disease but improves comfort.
- Sildenafil: A phosphodiesterase-5 inhibitor used to treat pulmonary hypertension. When pulmonary hypertension is documented, sildenafil can improve exercise tolerance and reduce right heart strain. Typical dose: 1-2 mg/kg two to three times daily.
Oxygen therapy:
- Supplemental oxygen at home can significantly improve quality of life in advanced disease. Oxygen concentrators and nasal prong delivery systems are available for home use.
- This is palliative, not curative, but it can extend comfortable time meaningfully.
Weight management:
- Obesity increases oxygen demand and breathing effort. Maintaining lean body condition is one of the most impactful interventions for any dog with compromised lung function.
12-Week Monitoring and Management Plan
- Weeks 1-2 (baseline): Full diagnostics including radiographs, echocardiography, and pulse oximetry at rest and after a 6-minute walk. Document baseline respiratory rate, exercise tolerance, and cough frequency.
- Weeks 3-4 (treatment trial): If steroids or bronchodilators are initiated, assess early response. Monitor resting respiratory rate daily (count breaths while sleeping).
- Weeks 5-6 (response evaluation): Recheck pulse oximetry. If sildenafil is started for pulmonary hypertension, assess exercise tolerance improvement.
- Weeks 7-8 (lifestyle optimization): Adjust activity level to match current capacity. Avoid heat, humidity, and high-altitude environments. Implement weight management if needed.
- Weeks 9-10 (quality of life tracking): Maintain a weekly quality-of-life log: exercise tolerance, breathing effort, appetite, engagement with family. Progressive decline in these metrics informs long-term decisions.
- Weeks 11-12 (long-term planning): Establish the monitoring cadence (typically every 2-3 months). Discuss supplemental oxygen if resting SpO2 is trending below 92%. Have an honest conversation with your veterinarian about prognosis and end-of-life planning.
Feeding and Nutritional Considerations
- Maintain lean body condition — even modest weight loss can improve breathing comfort
- Dogs with advanced fibrosis have elevated caloric expenditure from the work of breathing; ensure adequate caloric intake
- Omega-3 fatty acids may provide mild anti-inflammatory benefits
For guidance:
- Feeding Guide for Adult Dogs: Maintenance Nutrition Without Drift
- Omega-3 Fish Oil for Dogs: Evidence, Dosing Context, and Safety
- Weight Loss Feeding Protocol for Dogs — weight management is one of the most impactful interventions for reducing oxygen demand in dogs with compromised lung function
When to Go to the ER Today
- Blue or purple gums and tongue at rest
- Severe open-mouth breathing with visible abdominal effort
- Syncope (fainting/collapse) during or after exertion
- Acute worsening of breathing that does not resolve within 30 minutes of rest in a cool environment
- Refusal to eat or drink combined with progressive respiratory distress
Respiratory emergencies in dogs with pulmonary fibrosis can be difficult to stabilize. Know your emergency clinic’s location and after-hours availability.
Related Condition Pathways
- Chronic Bronchitis: Differential diagnosis for chronic cough in middle-aged and senior dogs
- Congestive Heart Failure: Pulmonary fibrosis with secondary pulmonary hypertension can lead to right-sided heart failure
- Tracheal Collapse: Another chronic cough differential, more common in toy breeds
- Mitral Valve Disease: Must be differentiated from pulmonary fibrosis as a cause of cough and exercise intolerance
Related Breed Longevity Guides
- West Highland White Terrier Lifespan & Longevity Guide
- Staffordshire Bull Terrier Lifespan & Longevity Guide
- Cavalier King Charles Spaniel Lifespan & Longevity Guide
- Jack Russell Terrier Lifespan & Longevity Guide
- Cairn Terrier Lifespan & Longevity Guide
Where This Condition Fits in Longevity Research
- Senior Dog Screening Protocol
- Canine Cardiac Monitoring Protocol
- Polypharmacy Management in Senior Dogs
Frequently Asked Questions
How long can a dog live with pulmonary fibrosis?
Survival time varies widely depending on the severity at diagnosis and the rate of progression. Some dogs live 12-18 months after diagnosis with good quality of life on symptomatic management. Others progress more slowly, particularly if diagnosed early. West Highland White Terriers with documented pulmonary fibrosis have a median survival of approximately 18 months from diagnosis in published studies.
Is pulmonary fibrosis painful?
The fibrosis itself is not directly painful, but the progressive air hunger (dyspnea) and the work of breathing create significant discomfort and distress. Quality-of-life management focuses on reducing this respiratory distress.
Can pulmonary fibrosis be caused by other diseases?
Yes. Chronic lung infections, radiation therapy, certain toxin exposures, and chronic aspiration can all cause secondary pulmonary fibrosis. These secondary forms may be partially treatable if the underlying cause is identified and addressed. Idiopathic pulmonary fibrosis, by definition, has no identifiable trigger.
Should I get a Westie puppy if pulmonary fibrosis is this common?
Pulmonary fibrosis is a significant health concern in the breed, but it does not affect every Westie. Choosing a breeder who screens for respiratory health and avoids breeding dogs with known fibrosis can reduce risk. Being aware of the condition means you can monitor for early signs and seek evaluation promptly.
Is there any research into new treatments?
Yes. Anti-fibrotic drugs used in human IPF (pirfenidone, nintedanib) are being explored in veterinary medicine. Stem cell therapy and other regenerative approaches are in early-stage investigation. These are not yet standard of care, but the field is advancing.
Medical Disclaimer
This content is educational and does not replace veterinary diagnosis or treatment. Dogs with chronic cough, exercise intolerance, or labored breathing need prompt veterinary evaluation.
References
- Corcoran BM et al. Chronic pulmonary disease in West Highland White Terriers. Vet Rec. 1999;144(22):611-616.
- Heikkila-Laurila HP, Rajamaki MM. Idiopathic pulmonary fibrosis in West Highland White Terriers. Vet Clin North Am Small Anim Pract. 2014;44(1):129-142.
- Kellihan HB et al. Pulmonary hypertension and its association with pulmonary fibrosis in West Highland White Terriers. J Vet Intern Med. 2012;26(3):648.
- Johnson LR, Vernau W. Bronchoscopic findings in 48 cats with spontaneous lower respiratory tract disease. J Vet Intern Med. 2011;25(2):236-243.
- Reinero C et al. ACVIM consensus statement on diagnosis of canine chronic bronchitis. J Vet Intern Med. 2019;33(3):975-990.
Related reads
Related Reading
Continue exploring
